COVID-19: viral infection, endotheliopathy and the immuno-inflammatory response… is it time to consider a standard (non-immunized) plasma therapy approach to maintain homeostasis?
Transfus Clin Biol
.
2022 Aug;29(3):191-194.
doi: 10.1016/j.tracli.2022.04.002.
Epub 2022 May 2.
Authors
Frédérique Dufour-Gaume
1
,
Emilie Javelle
2
,
Anne Sailliol
3
,
Andre P Cap
4
,
Nicolas J Prat
3
Affiliations
1
Institut de Recherche Biomédicale des Armées, France. Electronic address: frederique.dufour-gaume@def.gouv.fr.
2
Hôpital d'Instruction des Armées Laveran, Marseille, France.
3
Institut de Recherche Biomédicale des Armées, France.
4
U.S. Army Institute of Surgical Research, Houston, USA.
PMID:
35644840
PMCID:
PMC9059338
DOI:
10.1016/j.tracli.2022.04.002
No abstract available
Publication types
Editorial
MeSH terms
COVID-19* / therapy
Homeostasis
Humans
Plasma
SARS-CoV-2
Virus Diseases*